Anthem Biosciences Ltd
ANTHEM NSE
Anthem Biosciences Ltd
HealthcareNSE: ANTHEM BSE: 544449 Biotechnology
Key Fundamentals
MidcapBiotechnologyHealthcareMarket Cap
₹50,065 Cr
Volatility
High Risk
P/E Ratio
87.03
EBITDA
₹990 Cr
Return on Equity
19.45%
Debt to Equity
0.02
Book Value
₹54.03
52W High
₹904
52W Low
₹579.15
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Anthem Biosciences Ltd insights
52 extracted metrics + investor summaries across FY19–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
3- Company has reduced debt.
- Company is almost debt free.
- Company's working capital requirements have reduced from 118 days to 92.3 days
Weaknesses
2- Stock is trading at 16.6 times its book value
- Promoter holding has decreased over last quarter: -3.25%
Growth Rate
Revenue Growth
18.12% ↗
Net Income Growth
31.13% ↗
Cash Flow Change
212.14% ↗
ROE
3.84% ↗
ROCE
-0.41% ↗
EBITDA Margin (Avg.)
10.74% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoAI opinion · based on fundamentals
Risk high
Anthem Biosciences is a CRDMO with a market cap of approximately ₹49,857 crore, trading at a PE of 85.8x and 16.25x book value. The company delivered 26% compounded sales growth over 3 years and maintains ROE of ~22%, but TTM revenue has declined 2% and recent quarterly profit fell 11.67% YoY, signaling near-term softness despite a strong longer-term growth track record.
Bull Case 8
- 3-year compounded sales CAGR of 26% demonstrates strong top-line momentum over the medium term
- Consistent ROE of 21-23% over the last 3-5 years indicates efficient capital deployment
- Company is almost debt-free, reducing financial risk and interest burden
- FY26 consolidated revenue reached ₹2,124 crore with 18% annual growth, showing scale recovery
- Working capital days improved from 118 days to 92.3 days, freeing up cash for operations
- 5-year compounded profit CAGR of 17% reflects sustained earnings growth
- Integrated CRDMO model covering both small molecules and biologics provides diversified revenue streams and is rare in India
- 1-year stock CAGR of 16% shows positive market re-rating amid sector tailwinds for Indian CDMOs
Bear Case 8
- PE of 85.8x is significantly elevated, pricing in aggressive future growth with limited margin of safety
- Stock trades at 16.25x book value, implying high premium even relative to quality healthcare peers
- TTM compounded sales growth turned negative at -2%, indicating recent revenue deceleration
- Q1 FY27 net profit of ₹119.94 crore fell 36.79% QoQ and 11.67% YoY, signaling earnings volatility
- Promoter holding declined by 3.25% in the last quarter, which may indicate reduced insider confidence
- Dividend yield of just 0.23% offers negligible income return to shareholders at current valuations
- FY24 adjusted net profit of ₹367 crore was lower than FY23's ₹385 crore, showing profit is not consistently linear
- 52-week high/low data is unavailable (reported as 0), limiting visibility on recent price range and drawdown risk
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 17h ago Positives 1
- Confident on mid-teens growth Jul 22
Anthem Biosciences expressed confidence in regaining its mid-teens growth rate, signaling a positive business outlook though no specific timelines or financial metrics were provided.
Neutral 1
- 20th AGM resolutions approved Jul 22
Anthem Biosciences held its 20th AGM on July 22, 2026, approving FY 2025-26 financial statements and appointing statutory auditors.
TL;DR: Anthem Biosciences had a routine AGM with no red flags, and management struck an optimistic tone on returning to mid-teens revenue growth. No specific headwinds or negative developments surfaced in recent news. The forward outlook depends on whether the company can deliver on its growth confidence with concrete results in coming quarters.
Quarterly Results
| Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 339 | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 218 | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating Profit | 121 | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 36% | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other Income | 19 | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 19 | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| PBT | 118 | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 30% | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net Profit | 82 | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS in Rs | 1.47 | 2.9 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
Profit & Loss
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,002 |
| Expenses | 451 | 695 | 666 | 626 | 914 | 1,173 | 1,290 | 1,209 |
| Operating Profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% | 40% |
| Other Income | 21 | 37 | 49 | 139 | 63 | 85 | 131 | 133 |
| Interest | 20 | 17 | 10 | 9 | 10 | 11 | 7 | 6 |
| Depreciation | 62 | 62 | 58 | 64 | 82 | 89 | 134 | 138 |
| PBT | 121 | 366 | 546 | 497 | 477 | 657 | 824 | 783 |
| Tax % | 23% | 26% | 26% | 23% | 23% | 31% | 28% | — |
| Net Profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS in Rs | 111 | 320 | 462 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 19% | — |
Balance Sheet
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 54 |
| Other Liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 333 |
| Total Liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Fixed Assets | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 |
| Other Assets | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 |
| Total Assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
Cash Flow
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Operating | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Investing | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Financing | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net Cash Flow | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free Cash Flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO/OP | 116 | 85 | 81 | 98 | 51 | 64 | 126 |
Ratios
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory Days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days Payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash Conversion Cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working Capital Days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
| ROCE % | — | 55% | 51% | 28% | 24% | 28% | 30% |
Documents
1
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore. 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore.
2
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore. 30 Apr - Anthem Biosciences says it is not a Large Corporate; outstanding borrowing was INR 2.96 crore.
3
Announcement Under Regulation 30 Of LODR-Update In The Outcome Of The Board Meeting Held On April 22, 2026
22 Apr - Board approved S.R. Batliboi as auditor and sought approval for ₹1,276.83 million promoter payout from investor divestment. 22 Apr - Board approved S.R. Batliboi as auditor and sought approval for ₹1,276.83 million promoter payout from investor divestment.
4
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
22 Apr - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million. 22 Apr - Board approved SR Batliboi as statutory auditor for 5 years and an upside-sharing payout of INR 1,276.83 million.
5
Announcement Under Regulation 30 Of LODR-Update In The Outcome Of The Board Meeting Held On April 22, 2026
10h - Board approved S.R. Batliboi as auditor and sought approval for ₹1,276.83 million promoter payout from investor divestment. 10h - Board approved S.R. Batliboi as auditor and sought approval for ₹1,276.83 million promoter payout from investor divestment.
Frequently Asked Questions about Anthem Biosciences Ltd
What does Anthem Biosciences Ltd do?
Incorporated in 2006, Anthem Biosciences
Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
Where is Anthem Biosciences Ltd (ANTHEM) listed?
Anthem Biosciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: ANTHEM and BSE: 544449. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Anthem Biosciences Ltd belong to?
Anthem Biosciences Ltd operates in the Healthcare sector within the Biotechnology industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Anthem Biosciences Ltd?
Anthem Biosciences Ltd has a market capitalisation of approximately ₹50065.23 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Anthem Biosciences Ltd?
The Price-to-Earnings (PE) ratio of Anthem Biosciences Ltd is 87.03. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Anthem Biosciences Ltd?
Over the past 52 weeks, Anthem Biosciences Ltd has traded between a low of ₹579.15 and a high of ₹904. This range helps investors understand the stock's price volatility and recent trading levels.
Does Anthem Biosciences Ltd pay dividends?
Yes, Anthem Biosciences Ltd has a dividend yield of 0.22%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Anthem Biosciences Ltd?
Anthem Biosciences Ltd has a Return on Equity (ROE) of 19.45%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Anthem Biosciences Ltd on Tapetide?
On Tapetide, you can view Anthem Biosciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Incorporated in 2006, Anthem Biosciences Ltd is in the business of providing CRDMO services and the manufacture and sale of specialty ingredients.[1]
Website anthembio.com
CEO Mr. Ajay Bhardwaj B.Tech., M.S
Listed 2025-07-21
Face Value ₹ 2
Issued Size 56,16,10,051